CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $275.36M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 0.3: distress zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
275.36MUSDvs all stocks (USD)
Revenue (TTM)
58.37MUSDvs all stocks (USD)
Profit Margin
-183.90%vs Biotechnology peers
Beta
0.8070xvs all stocks
52-Week Change
-16.61%vs all stocks
Market Capitalization
275.36MUSDvs all stocks (USD)
Enterprise Value
123.67MUSDvs all stocks (USD)
Forward P/E
-1.70xvs Biotechnology peers
Price to Sales (TTM)
4.72xvs Biotechnology peers
Price to Book (MRQ)
1.52xvs Biotechnology peers
Enterprise to Revenue
2.12xvs Biotechnology peers
Enterprise to EBITDA
-1.10xvs Biotechnology peers
Gross Margin
91.09%vs Biotechnology peers
Profit Margin
-183.90%vs Biotechnology peers
Operating Margin
-320.76%vs Biotechnology peers
Return on Assets (TTM)
-45.67%vs Biotechnology peers
Return on Equity (TTM)
-95.89%vs Biotechnology peers
Revenue (TTM)
58.37MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.2160USDUpdated Sep 27, 2026Quarterly Revenue Growth
21.20%vs Biotechnology peers
Gross Profit (TTM)
53.83MUSDvs all stocks (USD)
EBITDA (TTM)
-111.89MUSDvs all stocks (USD)
Net Income (TTM)
-107.33MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
21.20%vs Biotechnology peers
Operating Cash Flow (TTM)
-108.42MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-69.95MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
53.43MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
3.75MUSDFY2025 · Dec 31, 2025Gross Profit
49.68MUSDFY2025 · Dec 31, 2025Operating Income
-55.56MUSDvs all stocks (USD)
Pre-tax Income
-52.49MUSDFY2025 · Dec 31, 2025Net Income
-52.49MUSDFY2025 · Dec 31, 2025EBIT
-55.56MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-53.45MUSDFY2025 · Dec 31, 2025Research & Development
38.31MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
66.93MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-52.49MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-40.21MUSDFY2025 · Dec 31, 2025Free Cash Flow
-40.37MUSDDerived from operating cash flow minus capital expenditure. This filing charges 2.11M of depreciation against 155K of capital expenditure, and its own free-cash-flow line reads -58.29M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
226.69MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-52.49MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.11MUSDFY2025 · Dec 31, 2025Stock-based Compensation
11.64MUSDFY2025 · Dec 31, 2025Other Non-cash Items
298.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-3.34MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.21MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.65MUSDFY2025 · Dec 31, 2025Capital Expenditures
-155.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-155.00KUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-633.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-336.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
214.97MUSDFY2025 · Dec 31, 2025Shares Outstanding
294.76MSharesUpdated Sep 27, 2026Float Shares
207.83MSharesUpdated Sep 27, 2026Shares Short
30.56MSharesUpdated Sep 27, 2026Short Ratio
7.08daysvs all stocks
Short % of Shares Outstanding
11.45%vs all stocks
% Held by Insiders
7.16%vs all stocks
% Held by Institutions
86.88%vs all stocks
Total Cash (MRQ)
160.08MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.5430USDUpdated Sep 27, 2026Total Debt (MRQ)
8.39MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0463xvs Biotechnology peers
Current Ratio (MRQ)
5.87xvs Biotechnology peers
Book Value per Share (MRQ)
0.6140USDUpdated Sep 27, 2026Total Assets
276.88MUSDvs all stocks (USD)
Total Current Assets
247.47MUSDFY2025 · Dec 31, 2025Total Liabilities
35.34MUSDFY2025 · Dec 31, 2025Total Non-current Assets
29.42MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.18MUSDFY2025 · Dec 31, 2025Total Current Liabilities
34.16MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
226.69MUSDFY2025 · Dec 31, 2025Accounts Receivable
13.92MUSDFY2025 · Dec 31, 2025Inventory
263.00KUSDFY2025 · Dec 31, 2025Accounts Payable
13.74MUSDFY2025 · Dec 31, 2025Short-term Debt
1.31MUSDFY2025 · Dec 31, 2025Other Current Liabilities
52.00KUSDFY2025 · Dec 31, 2025Long-term Debt
1.18MUSDFY2025 · Dec 31, 2025Common Stock (Book)
28.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-954.48MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
241.54MUSDvs all stocks (USD)
52-Week Low
0.5280USDUpdated Sep 27, 202652-Week High
3.07USDUpdated Sep 27, 202652-Week Change
-16.61%vs all stocks
Beta
0.8070xvs all stocks
50-Day MA
0.7746USDUpdated Sep 27, 2026200-Day MA
1.40USDUpdated Sep 27, 2026Avg 10-Day Volume
6.36MSharesUpdated Sep 27, 2026Avg 30-Day Volume
4.94MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-0.3100USDUpdated Sep 27, 2026Other Income / Expense
3.07MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.91Profit Margin: -1.84
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 5.87Altman Z-Score: 0.30
Financial Health
Altman Z-Score 0.3: distress zoneCritical
Altman Z-Score: 0.30
Low earnings qualitySignificant
Earnings Quality Score: -0.50
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $275.36M, lower than 95% of all stocks globallySignificant
Market cap (USD): 275,363,617Global P5: 275,556,405.438
Companies that share the same coordination system — how they create, deliver, or capture value.
Cresco Labs Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Immuneering Corporation
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Jiaying Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Northwest Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tiansheng Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lexeo Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Elite Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sichuan Gangtong Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hunan Nucien Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Ginwa Enterprise Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Chengdu Zhimingda Electronics Co., Ltd.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And DrawdownIndustry-Benchmarked ROA and Margin Elevated
ABL Bio Inc.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And DrawdownIndustry-Benchmarked ROA and Margin Elevated
Myson Century Inc.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And DrawdownIndustry-Benchmarked ROA and Margin Elevated